China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 11.99 billion. The enterprise value is 10.50 billion.
| Market Cap | 11.99B |
| Enterprise Value | 10.50B |
Important Dates
The last earnings date was Saturday, August 1, 2026.
| Earnings Date | Aug 1, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
Guobang Pharma has 772.00 million shares outstanding. The number of shares has decreased by -1.87% in one year.
| Current Share Class | 772.00M |
| Shares Outstanding | 772.00M |
| Shares Change (YoY) | -1.87% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 12.86% |
| Owned by Institutions (%) | 16.10% |
| Float | 323.40M |
Valuation Ratios
The trailing PE ratio is 16.96.
| PE Ratio | 16.96 |
| Forward PE | n/a |
| PS Ratio | 1.96 |
| PB Ratio | 1.43 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | 25.92 |
| P/OCF Ratio | 13.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.05, with an EV/FCF ratio of 22.71.
| EV / Earnings | 14.87 |
| EV / Sales | 1.71 |
| EV / EBITDA | 8.05 |
| EV / EBIT | 12.86 |
| EV / FCF | 22.71 |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.33 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.79 |
| Debt / FCF | 2.22 |
| Interest Coverage | 35.15 |
Financial Efficiency
Return on equity (ROE) is 8.56% and return on invested capital (ROIC) is 10.21%.
| Return on Equity (ROE) | 8.56% |
| Return on Assets (ROA) | 4.60% |
| Return on Invested Capital (ROIC) | 10.21% |
| Return on Capital Employed (ROCE) | 9.49% |
| Weighted Average Cost of Capital (WACC) | 5.06% |
| Revenue Per Employee | 1.44M |
| Profits Per Employee | 166,219 |
| Employee Count | 4,251 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.78 |
Taxes
In the past 12 months, Guobang Pharma has paid 112.89 million in taxes.
| Income Tax | 112.89M |
| Effective Tax Rate | 13.80% |
Stock Price Statistics
The stock price has decreased by -6.81% in the last 52 weeks. The beta is 0.20, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -6.81% |
| 50-Day Moving Average | 15.68 |
| 200-Day Moving Average | 17.14 |
| Relative Strength Index (RSI) | 46.21 |
| Average Volume (20 Days) | 7,911,975 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 6.13 billion and earned 706.60 million in profits. Earnings per share was 0.92.
| Revenue | 6.13B |
| Gross Profit | 1.46B |
| Operating Income | 816.86M |
| Pretax Income | 817.79M |
| Net Income | 706.60M |
| EBITDA | 1.30B |
| EBIT | 816.86M |
| Earnings Per Share (EPS) | 0.92 |
Balance Sheet
The company has 2.51 billion in cash and 1.03 billion in debt, with a net cash position of 1.49 billion or 1.93 per share.
| Cash & Cash Equivalents | 2.51B |
| Total Debt | 1.03B |
| Net Cash | 1.49B |
| Net Cash Per Share | 1.93 |
| Equity (Book Value) | 8.40B |
| Book Value Per Share | 10.88 |
| Working Capital | 3.70B |
Cash Flow
In the last 12 months, operating cash flow was 911.35 million and capital expenditures -448.84 million, giving a free cash flow of 462.51 million.
| Operating Cash Flow | 911.35M |
| Capital Expenditures | -448.84M |
| Depreciation & Amortization | 487.68M |
| Net Borrowing | 85.53M |
| Free Cash Flow | 462.51M |
| FCF Per Share | 0.60 |
Margins
Gross margin is 23.87%, with operating and profit margins of 13.33% and 11.53%.
| Gross Margin | 23.87% |
| Operating Margin | 13.33% |
| Pretax Margin | 13.35% |
| Profit Margin | 11.53% |
| EBITDA Margin | 21.28% |
| EBIT Margin | 13.33% |
| FCF Margin | 7.55% |
Dividends & Yields
This stock pays an annual dividend of 0.43, which amounts to a dividend yield of 2.76%.
| Dividend Per Share | 0.43 |
| Dividend Yield | 2.76% |
| Dividend Growth (YoY) | 38.65% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 50.21% |
| Buyback Yield | 1.87% |
| Shareholder Yield | 4.63% |
| Earnings Yield | 5.89% |
| FCF Yield | 3.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2026. It was a forward split with a ratio of 1.4.
| Last Split Date | May 29, 2026 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Guobang Pharma has an Altman Z-Score of 4.36 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.36 |
| Piotroski F-Score | 5 |